NanoViricides' NV-387 May Reduce Cancer Resurgence Risk Linked to Viral Infections

NanoViricides' experimental antiviral drug NV-387 may help lower the risk of metastatic cancer returning in patients following viral infections by reducing inflammation markers. The company said recent studies have found that inflammation caused by infections such as COVID-19 and influenza can reactivate dormant cancer cells, leading to the resurgence of metastatic disease. NV-387 has shown the ability to reduce IL-6 and other inflammation markers in preclinical studies and early testing.